All In Biotech

BLA 125499 · Biogen Idec INC

Plegridy

Peginterferon Beta-1a · Injection · Interferon beta

Novel

Last checked: Nov 20, 2026Latest source record: Jul 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Aug 15, 2014

Approved uses

3

Original approval plus efficacy supplements

Registered trials

22

8 Phase 3, 0 recruiting

FAERS reports

13,098

5,630 serious, 336 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 12, 2025.

PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PLEGRIDY is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 )

Mechanism: The mechanism by which PLEGRIDY exerts its effects in patients with multiple sclerosis is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PLEGRIDY · PEGINTERFERON BETA-1A 125MICROGRAMS/0.5ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Peginterferon Beta-1a" as an intervention, any sponsor and status, largest first.

All 22 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • influenza like illness1,470
  • injection site erythema1,065
  • multiple sclerosis relapse979
  • fatigue715
  • headache619
  • pain609
  • injection site reaction580
  • device malfunction572
  • multiple sclerosis566
  • pyrexia522
  • memory impairment474
  • malaise471

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
201418
2015646
20162,699
20171,997
20181,831
20191,326
20201,077
2021919
2022808
2023610
2024463
2025465
2026238

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Plegridy* (PEGinterferon Beta-1a)

2024 spending

$5.6M

Beneficiaries

89

536 claims

Per beneficiary

$63,164

$8,104.07 per unit

View as table
YearSpending
2020$9,407,505
2021$8,642,617
2022$8,056,429
2023$6,466,500
2024$5,621,558

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 25 on PubMed

Sponsor: Biogen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.